**Core Concept**
The management of congestive heart failure (CHF) involves the use of various pharmacological agents to improve symptoms, increase exercise tolerance, and enhance survival. The long-term treatment of CHF often involves the use of neurohormonal antagonists, vasodilators, and inotropes to counteract the pathophysiological mechanisms underlying the disease.

**Why the Correct Answer is Right**
The treatment of CHF focuses on reducing the neurohormonal activation that contributes to disease progression. Angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, and aldosterone antagonists are commonly used in the long-term management of CHF to reduce morbidity and mortality. These agents counteract the effects of the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system activation, which play a crucial role in the pathophysiology of CHF.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is not typically used in the long-term treatment of CHF. However, it may be considered in certain cases, such as in patients with severe hypertension or acute decompensated heart failure.
**Option B:** This option is incorrect because ACE inhibitors are commonly used in the long-term treatment of CHF to reduce morbidity and mortality.
**Option C:** This option is incorrect because beta-blockers are essential in the long-term management of CHF to reduce the risk of hospitalization and improve survival.

**Clinical Pearl / High-Yield Fact**
In the management of CHF, it is essential to identify and address the underlying cause of the condition, such as hypertension, coronary artery disease, or valvular disease. The use of neurohormonal antagonists, vasodilators, and inotropes can help to improve symptoms and enhance survival in patients with CHF.

**Correct Answer: D.**